Form 4: Halozyme Therapeutics SVP Exercises Stock Options
SEC Form 4 Filing
Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised options to purchase 5,580 shares of common stock at $18.41 on August 27, 2024.
Summary
- On August 27, 2024, Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, exercised options to acquire 5,580 shares of common stock at a price of $18.41 per share.
- Following the transaction, LaBarre directly owns 173,756 shares of Halozyme Therapeutics common stock.
- The options exercised were granted on February 14, 2018, and vested over time.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of an executive exercising stock options, which doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
- It provides transparency into executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 02/14/2018 | Date the options were granted |
| 08/27/2024 | Date of the transaction (option exercise) |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.